Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers [Research Articles]
This article is highlighted in the In This Issue feature, p. 539
Source: Cancer Discovery - Category: Cancer & Oncology Authors: de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A., Wainberg, Z. A. Tags: Research Articles Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Study | Thrombocytopenia